Gajos-Michniewicz Anna, Czyz Malgorzata
Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215 Lodz, Poland.
Int J Mol Sci. 2024 Nov 28;25(23):12804. doi: 10.3390/ijms252312804.
Targeted therapies and immunotherapies have improved the clinical outcome of cancer patients; however, the efficacy of treatment remains frequently limited due to low predictability of response and development of drug resistance. Therefore, novel therapeutic strategies for various cancer types are needed. Current research emphasizes the potential therapeutic value of targeting WNT/β-catenin dependent signaling that is deregulated in various cancer types. Targeting the WNT/β-catenin signaling pathway with diverse synthetic and natural agents is the subject of a number of preclinical studies and clinical trials for cancer patients. The usage of nature-derived agents is attributed to their health benefits, reduced toxicity and side effects compared to synthetic agents. The review summarizes preclinical studies and ongoing clinical trials that aim to target components of the WNT/β-catenin pathway across a diverse spectrum of cancer types, highlighting their potential to improve cancer treatment.
靶向治疗和免疫疗法改善了癌症患者的临床结局；然而，由于反应的可预测性低和耐药性的产生，治疗效果仍然常常受到限制。因此，需要针对各种癌症类型的新型治疗策略。当前的研究强调了靶向WNT/β-连环蛋白依赖性信号传导的潜在治疗价值，该信号传导在各种癌症类型中失调。使用多种合成和天然药物靶向WNT/β-连环蛋白信号通路是针对癌症患者的多项临床前研究和临床试验的主题。与合成药物相比，天然衍生药物的使用归因于其健康益处、更低的毒性和副作用。这篇综述总结了旨在靶向多种癌症类型中WNT/β-连环蛋白通路成分的临床前研究和正在进行的临床试验，强调了它们改善癌症治疗的潜力。
